June 5th 2023
Daré Bioscience has announced positive results from a phase 2b trial analyzing the safety and efficacy of sildenafil cream, 3.6% in women with female sexual arousal disorder.
Community Practice Connections™: Translating Recent Evidence on CAR T-Cell Therapy to the Real-World Management of Lymphoid Malignancies
View More
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Medical Crossfire®: Experts Address Burning Questions in DLBCL—Sequencing CD19-Targeted Therapies, Strategies Post-CAR T Relapse, Novel Agents, and More!
View More
Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
On-Demand Video Updates from the Annual Oncology Meeting
View More
Expert Illustrations and Commentaries™: Placing New MPN Therapies Into Context Through Illustrated Case Discussions
View More
Advances In™: The Role of NRG1 Fusions Across Tumor Types
View More
Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
View More
Patient, Provider, and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of TNBC
View More
Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
View More
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
View More
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
View More
Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
View More
Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
View More
Medical Crossfire®: Evaluating the Potential Role of Next-Generation Selective Estrogen Receptor Degraders in the ER+/HER2- Breast Cancer Treatment Paradigm
View More
Hot Seat™: Expert Considerations to Maximize the Clinical Benefits of Targeted Therapies in Patients With Relapsed/Refractory DLBCL
View More
22nd Annual International Congress on the Future of Breast Cancer® East
View More
22nd Annual International Congress on the Future of Breast Cancer® East
View More
BURST CME™: Exploring the Biologic Rationale for Novel IRAK4-directed Therapy for the Treatment of High Risk MDS and AML
View More
Medical Crossfire®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?
View More
4th Annual International Congress on the Future of Women’s Health™
07/22/2023
View More
Advances In: Interprofessional Strategies to Optimize Outcomes for Patients with Relapsed/Refractory Multiple Myeloma: Expert Discussions to Maximize Safety and Efficacy
View More
Community Practice Connections™: Incorporating Novel Therapies Into Treatment Algorithms Across Acute and Chronic GVHD
View More
Clinical Vignettes™: Testing and Treatment Strategies in Cholangiocarcinoma
View More
22nd Annual International Congress on the Future of Breast Cancer® West
View More
22nd Annual International Congress on the Future of Breast Cancer® West
View More
FDA approves dostarlimab for dMMR endometrial cancer
February 10th 2023The FDA has granted a regular approval to dostarlimab-gxly (Jemperli; GSK) for adult patients with mismatch repair–deficient, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Read More
Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.
Read More
FDA approves IUD to prevent pregnancy for up to 8 years
November 15th 2022The Food and Drug Administration (FDA) has approved Medicine360’s supplemental new drug application to extend the use of its levongestrel-releasing intrauterine system 52mg (LILETTA) to prevent pregnancy for up to 8 years.
Read More
Whooping cough vaccine approved for use during third trimester
October 7th 2022The US Food & Drug Administration approved tetanus toxoid, reduced diptheria toxoid and acellular pertussis vaccine, adsorbed [Tdap] (Boostrix, GSK) today for immunization during the third trimester of pregnancy to prevent pertussis—or whooping cough—in infants under 2 months of age.
Read More